Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Pfizer Earnings Preview: What to Expect

With a market cap of $145.7 billion, Pfizer Inc. (PFE) is a global, research-driven biopharmaceutical company, specializing in the discovery, development, and commercialization of innovative medicines and vaccines across diverse therapeutic areas. With a strong late-stage pipeline and strategic partnerships, Pfizer maintains a robust presence in both established and emerging healthcare markets.

The New York-based company is slated to announce its fiscal Q2 2025 results before the market opens on Tuesday, Aug. 5. Ahead of the event, analysts predict Pfizer to report an adjusted EPS of $0.57, down 5% from $0.60 in the year-ago quarter. However, the company has surpassed Wall...

Fundamentals

See More
  • Market Capitalization, $K 145,659,088
  • Shares Outstanding, K 5,685,366
  • Annual Sales, $ 63,627 M
  • Annual Income, $ 8,031 M
  • EBIT $ 17,236 M
  • EBITDA $ 24,249 M
  • 60-Month Beta 0.58
  • Price/Sales 2.26
  • Price/Cash Flow 5.78
  • Price/Book 1.58

Options Overview Details

View History
  • Implied Volatility 26.21% ( +1.06%)
  • Historical Volatility 17.91%
  • IV Percentile 56%
  • IV Rank 20.62%
  • IV High 52.17% on 04/10/25
  • IV Low 19.47% on 09/24/24
  • Put/Call Vol Ratio 1.14
  • Today's Volume 81,492
  • Volume Avg (30-Day) 96,926
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 2,839,459
  • Open Int (30-Day) 2,966,535

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 0.57
  • Number of Estimates 5
  • High Estimate 0.60
  • Low Estimate 0.55
  • Prior Year 0.60
  • Growth Rate Est. (year over year) -5.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.76 +7.55%
on 06/23/25
25.96 -1.54%
on 07/08/25
+1.59 (+6.63%)
since 06/09/25
3-Month
21.08 +21.22%
on 04/10/25
25.96 -1.54%
on 07/08/25
+3.07 (+13.65%)
since 04/09/25
52-Week
20.92 +22.21%
on 04/09/25
31.54 -18.96%
on 07/30/24
-2.16 (-7.79%)
since 07/09/24

Most Recent Stories

More News
Pfizer Earnings Preview: What to Expect

Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company’s bottom-line figure.

XLV : 135.49 (+0.39%)
$SPX : 6,263.26 (+0.61%)
PFE : 25.56 (-0.23%)
Merck Faces Multiple Challenges: Will It Steer Through Successfully?

Merck MRK is expected to face several hurdles over the next few years that could affect its long-term growth trajectory, starting with the anticipated loss of exclusivity of its blockbuster PD-L1 inhibitor,...

JNJ : 156.28 (+0.31%)
MRK : 83.71 (+2.88%)
LLY : 786.92 (+1.19%)
PFE : 25.56 (-0.23%)
JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?

Johnson & Johnson JNJ and Pfizer PFE rank among the world’s largest pharmaceutical companies, each with broad and diversified healthcare portfolios. J&J operates primarily through its pharmaceuticals...

JNJ : 156.28 (+0.31%)
PFE : 25.56 (-0.23%)
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6...

AZN : 70.82 (+1.14%)
MRK : 83.71 (+2.88%)
PFE : 25.56 (-0.23%)
BMY : 47.66 (+1.32%)
3 Disappointing Blue Chip Stocks That Have Crashed as Much as 87% in 10 Years

$SPX : 6,263.26 (+0.61%)
WBA : 11.58 (+0.52%)
KHC : 26.45 (+0.08%)
PFE : 25.56 (-0.23%)
Top 5 Undervalued Dividend Stocks With Strong Payout Potential

Seemingly undervalued dividend stocks, such as BAC, F, MO, VZ, and PFE, offer a rare combination of strong yields and attractive valuations.

MO : 57.75 (-3.01%)
BAC : 46.84 (-0.66%)
VZ : 42.61 (-1.05%)
F : 11.83 (+1.28%)
PFE : 25.56 (-0.23%)
Warren Buffett Owns 9 Ultra-High-Yield Dividend Stocks. Here's the Best of the Bunch.

FYBR : 36.57 (unch)
VZ : 42.61 (-1.05%)
CVX : 153.02 (-0.14%)
KHC : 26.45 (+0.08%)
BRK.TO : 35.66 (+0.37%)
SIRI : 24.27 (-0.70%)
PFE : 25.56 (-0.23%)
O : 56.92 (-0.99%)
BMY : 47.66 (+1.32%)
ARCC : 22.52 (+0.45%)
CPB : 30.74 (-0.97%)
LAMR : 124.48 (+0.73%)
The Best Dividend Stocks I'd Buy Right Now

PFF : 31.19 (+0.61%)
CVX : 153.02 (-0.14%)
CAT : 402.18 (+2.00%)
UPS : 102.15 (-0.22%)
SCHD : 27.29 (-0.11%)
VYM : 134.95 (+0.18%)
PFE : 25.56 (-0.23%)
FDVV : 53.09 (+0.57%)
2 Stocks to Buy With Less Than $50

EXEL : 44.07 (+1.29%)
PFE : 25.56 (-0.23%)
Prediction: 3 Magnificent Stocks That'll Be Worth More Than Palantir by 2028

The parabolic ascent of artificial intelligence (AI) superstar Palantir Technologies may be short-lived.

PYPL : 74.83 (-0.27%)
ISRG : 528.13 (+0.16%)
PFE : 25.56 (-0.23%)
PLTR : 143.13 (+2.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 26.32
2nd Resistance Point 26.08
1st Resistance Point 25.82
Last Price 25.56
1st Support Level 25.32
2nd Support Level 25.08
3rd Support Level 24.82

See More

52-Week High 31.54
Fibonacci 61.8% 27.48
Fibonacci 50% 26.23
Last Price 25.56
Fibonacci 38.2% 24.97
52-Week Low 20.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar